• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by argenx SE

    12/17/25 4:10:48 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARGX alert in real time by email
    S-8 1 tm2533221d1_s8.htm FORM S-8

     

    As filed with the U.S. Securities and Exchange Commission on December 17, 2025

     

    Registration No. 333-

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

     

    ARGENX SE

    (Exact name of registrant as specified in its charter)

     

    The Netherlands   Not applicable
    (State or other jurisdiction of
    incorporation or organization)
      (I.R.S. Employer
    Identification Number)

     

    Laarderhoogtweg 25
    1101 EB Amsterdam, the Netherlands
    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    argenx Equity Incentive Plan, as amended

    (Full title of the plan)

     

    CT Corporation System
    111 Eighth Avenue
    New York, New York 10011

    +1 (212) 894-8940

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Pamela L. Marcogliese, Esq.

    Erik F. Gerding, Esq.

    Freshfields US LLP

    3 World Trade Center

    175 Greenwich Street

    New York, NY 10007

    (212) 277-4000

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer x Accelerated filer ¨
    Non-accelerated filer ¨ Smaller reporting company ¨

      Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

    ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 registers additional ordinary shares under the Registrant’s Equity Incentive Plan, as amended.

     

    PART I.

     

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    The information specified in Part I of Form S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 424 under the Securities Act and the introductory note to Part I of this Registration Statement. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants in the plans covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.

     

    PART II.

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    ITEM 3. INCORPORATION OF DOCUMENTS BY REFERENCE

     

    The following documents filed by argenx SE (the “Registrant”) with the U.S. Securities and Exchange Commission (the “Commission”) are incorporated by reference into this Registration Statement:

     

    (a) The Registrant’s Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Commission on March 20, 2025, which contains audited financial statements for the Registrant’s latest fiscal year for which such statements have been filed;

     

    (b) The Registrant’s reports on Form 6-K furnished to the Commission on January 13, 2025, February 27, 2025, March 7, 2025, March 20, 2025, April 8, 2025, April 11, 2025, April 14, 2025, April 28, 2025, May 8, 2025, May 28, 2025, June 11, 2025, June 20, 2025, June 30, 2025, July 31, 2025, August 25, 2025, October 3, 2025, October 15, 2025, October 29, 2025, October 30, 2025, November 18, 2025 and December 15, 2025 (other than portions of each of the foregoing expressly excluded from incorporation by reference); and

     

    (c) The description of the Registrant’s Ordinary Shares and American Depositary Shares contained in the Registrant’s Registration Statement on Form 8-A filed with the Commission under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) on May 16, 2017 (File No. 001-38097), including any amendment or report filed for the purpose of updating such description.

     

    All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any report on Form 6-K furnished by the Registrant to the Commission after the date of this Registration Statement (or a portion thereof) is incorporated by reference in this Registration Statement only to the extent that the report expressly states that the Registrant incorporates it (or such portions) by reference in this Registration Statement and it is not subsequently superseded. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    ITEM 4. DESCRIPTION OF SECURITIES

     

    Not applicable.

     

    ITEM 5. INTERESTS OF NAMED EXPERTS AND COUNSEL

     

    Not applicable.

     

    ITEM 6. INDEMNIFICATION OF DIRECTORS AND OFFICERS

     

    Under Dutch law, the Registrant’s board of directors and certain other officers may be held liable for damages in the event of improper or negligent performance of their duties. They may be held jointly and severally liable for damages to the Registrant and to third parties for infringement of the Articles of Association or of certain provisions of the Dutch Civil Code. In certain circumstances, they may also incur additional specific civil and criminal liabilities. Directors and certain other officers are insured under an insurance policy taken out by the Registrant against damages resulting from their conduct when acting in the capacities as such directors or officers. In addition, the Registrant’s Articles of Association provide for indemnification of our (former) directors and (former) officers, including reimbursement for legal fees and damages or fines based on acts or failures to act in their duties. No indemnification shall be given to a member of the Registrant’s board of directors in relation to claims insofar as they relate to the gaining in fact of personal profits, advantages or remuneration to which the relevant person was not legally entitled, or if the relevant person has been adjudged to be liable for willful misconduct or intentional recklessness. Such indemnification shall be deemed not to preclude any other rights to which those indemnified may be entitled otherwise.

     

    The Registrant has entered into indemnification agreements with each of the Registrant’s non-executive directors and each member of its executive management.

     

    In the underwriting agreements the Registrant entered into in connection with its May 2017 initial U.S. public offering and each of its December 2017, September 2018, November 2019, May 2020, February 2021, March 2022 and July 2023 U.S. follow-on offerings, the underwriters agreed to indemnify, under certain conditions, the Registrant, the members of the Registrant’s board of directors and persons who control the Registrant within the meaning of the Securities Act against certain liabilities, but only to the extent that such liabilities are caused by information relating to the underwriters furnished to the Registrant in writing expressly for use in the Registrant’s registration statement and certain other disclosure documents.

     

    ITEM 7. EXEMPTION FROM REGISTRATION CLAIMED

     

    Not applicable.

     

    ITEM 8. EXHIBITS

     

    See the Exhibit Index below for a list of exhibits filed as a part of, or incorporated by reference into, this Registration Statement, which Exhibit Index is incorporated herein by reference.

     

    ITEM 9. UNDERTAKINGS

     

    1. The undersigned Registrant hereby undertakes:

     

    (a) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

     

     

     

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement;

     

    Provided, however, that paragraphs (a)(i) and (a)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.

     

    (b) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (c) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    2. The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    3. Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit
    Number
      Description
    4.1(1)   Articles of Association, as amended (English translation).
    4.2(2)   Form of Deposit Agreement and Form of American Depositary Receipt.
    5.1*   Opinion of Freshfields LLP.
    23.1*   Consent of Deloitte Accountants B.V.
    23.2*   Consent of Freshfields LLP (included in Exhibit 5.1).
    24.1*   Power of Attorney (included on the signature page).
    99.1(3)   argenx Equity Incentive Plan, as amended (English translation).
    107*   Filing Fee Table.

     

    (1) Filed as Exhibit 1.1 to the Registrant’s Annual Report on Form 20-F (File No. 001-38097) filed with the Commission on March 20, 2025, and incorporated herein by reference.
    (2) Filed as Exhibits 4.1 and 4.2 to the Registrant’s Registration Statement on Form F-1/A (File No. 333-217417) filed with the Commission on May 16, 2017, and incorporated herein by reference.
    (3) Filed as Exhibit 4.3 to the Registrant’s Annual Report on Form 20-F (File No. 001-38097) filed with the Commission on March 20, 2025, and incorporated herein by reference.
    * Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Amsterdam, the Netherlands on December 17, 2025.

     

      ARGENX SE
         
      By: /s/ Tim Van Hauwermeiren
        Tim Van Hauwermeiren
        Chief Executive Officer

     

     

     

     

    POWER OF ATTORNEY

     

    We, the undersigned directors, officers and/or authorized representative in the United States of argenx SE, hereby severally constitute and appoint Tim Van Hauwermeiren and Karl Gubitz, and each of them singly, our true and lawful attorneys-in-fact and agents, with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the registration statement on Form S-8 filed herewith, and any and all pre-effective and post-effective amendments to said registration statement, under the Securities Act of 1933, as amended, in connection with the registration under the Securities Act of 1933, as amended, of equity securities of argenx SE, and to file or cause to be filed the same, with all exhibits thereto and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as each of them might or could do in person, and hereby ratifying and confirming all that said attorneys-in-fact and agents, and each of them, or their substitute or substitutes, shall do or cause to be done by virtue of this Power of Attorney.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Tim Van Hauwermeiren   Chief Executive Officer and Director (Principal Executive Officer)   December 17, 2025
    Tim Van Hauwermeiren        
             
    /s/ Karl Gubitz   Chief Financial Officer (Principal Financial and Accounting Officer)   December 17, 2025
    Karl Gubitz        
             
    /s/ Peter Verhaeghe   Chairperson of the Board   December 17, 2025
    Peter Verhaeghe        
             
    /s/ Anthony Rosenberg   Director (and Vice Chairperson)   December 17, 2025
    A.A. Rosenberg        
             
    /s/ Ana Cespedes   Director   December 17, 2025
    Ana Cespedes        
             
    /s/ James Daly   Director   December 17, 2025
    James Daly        
             
    /s/ Pamela M. Klein   Director   December 17, 2025
    Pamela M. Klein        
             
    /s/ Steve Krognes   Director   December 17, 2025
    Steve Krognes        
             
    /s/ Brian Kotzin   Director   December 17, 2025
    Brian Kotzin        
             
    /s/ Camilla Sylvest   Director   December 17, 2025
    Camilla Sylvest        

     

     

     

     

    SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES

     

    Pursuant to the Securities Act of 1933, as amended, the undersigned, the duly appointed representative in the United States of argenx SE has signed this registration statement on December 17, 2025.

     

    Puglisi & Associates    
         
           
    By: /s/ Donald J. Puglisi   Authorized Representative in the United States
      Name: Donald J. Puglisi    
      Title: Managing Director    

     

     

     

    Get the next $ARGX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARGX

    DatePrice TargetRatingAnalyst
    12/18/2025$858.00Outperform → Neutral
    Robert W. Baird
    11/24/2025Outperform → Peer Perform
    Wolfe Research
    9/15/2025$918.00Buy
    Truist
    9/11/2025Buy → Hold
    Deutsche Bank
    8/25/2025$850.00Outperform
    RBC Capital Mkts
    7/8/2025Hold → Buy
    Deutsche Bank
    7/3/2025$700.00Overweight
    Morgan Stanley
    5/13/2025$680.00Neutral → Outperform
    Robert W. Baird
    More analyst ratings

    $ARGX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG

    January 13, 2026, 7:00 AM CET  Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a supplemental Biologics License Application (sBLA) for VYVGART® (IV: efgartigimod alfa-fcab) for the treatment of adults with acetylcholine receptor antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). The application has been granted a Prescription Drug User Fee Act (PDUFA) target action date of May 10, 2026. "Patients living with seronegative gMG continue to face lim

    1/13/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx Highlights 2026 Strategic Priorities

    Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19,000 patients on treatment; and if approved, AChR-Ab seronegative gMG launch expected by end of 2026 Four registrational readouts expected in 2026, including first for empasiprubart, to advance toward next wave of 2027 commercial launches Successfully advanced four new pipeline molecules in 2025; three new molecules to enter Phase 1 in 2026, contributing to total of 10 clinical-stage molecules by year-end January 12, 2026, 7:00 a.m. CETAmsterdam, the Netherlands – argenx ((Euronext &, NASDA

    1/12/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx to Present at 44th Annual J.P. Morgan Healthcare Conference

    January 6, 2026Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Tim Van Hauwermeiren, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT. A live webcast of the presentation may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately 30 days following the presentation. About argenx argenx is a global immunology company committed to improving the lives

    1/6/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARGX
    SEC Filings

    View All

    SEC Form 6-K filed by argenx SE

    6-K - ARGENX SE (0001697862) (Filer)

    1/13/26 6:05:08 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by argenx SE

    6-K - ARGENX SE (0001697862) (Filer)

    1/12/26 4:05:56 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by argenx SE

    6-K - ARGENX SE (0001697862) (Filer)

    1/5/26 7:26:04 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARGX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    argenx downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded argenx from Outperform to Neutral and set a new price target of $858.00

    12/18/25 8:54:11 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx downgraded by Wolfe Research

    Wolfe Research downgraded argenx from Outperform to Peer Perform

    11/24/25 8:14:37 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Truist resumed coverage on argenx with a new price target

    Truist resumed coverage of argenx with a rating of Buy and set a new price target of $918.00

    9/15/25 7:47:59 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARGX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by argenx SE

    SC 13G/A - ARGENX SE (0001697862) (Subject)

    11/14/24 1:22:37 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by argenx SE

    SC 13G/A - ARGENX SE (0001697862) (Subject)

    11/12/24 9:50:11 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by argenx SE (Amendment)

    SC 13G/A - ARGENX SE (0001697862) (Subject)

    2/14/24 10:03:02 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARGX
    Financials

    Live finance-specific insights

    View All

    argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

    $1.13 billion in third quarter global product net sales  On track to submit seronegative gMG sBLA by year-end and report ADAPT-OCULUS results in 1H26 – supporting pursuit of broadest MG label of any biologic Five registrational study readouts expected in 2026 from leading immunology pipeline Management to host conference call today at 1:30 PM CET (8:30 AM ET) October 30, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its third quarter 2025 financial results and provided a business update. "argenx continues to deliver on

    10/30/25 2:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025

    October 23, 2025Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, October 30, 2025 at 1:30 PM CET (8:30 AM ET) to discuss its third quarter 2025 financial results and provide a business update. A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Dial-in numbers: Belgium                32 800 50 201Franc

    10/23/25 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update

    $949 million in second quarter global product net sales VYVGART SC launch in CIDP progresses with more than 2,500 patients on treatment globally ARGX-119 to advance to registrational study in CMS following positive proof of concept data; three additional topline data readouts across pipeline remain on track for second half of 2025 Management to host conference call today at 2:30 PM CET (8:30 AM ET) July 31, 2025 7:00 AM CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its half year 2025 results and provided a second quarter business up

    7/31/25 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARGX
    Leadership Updates

    Live Leadership Updates

    View All

    argenx Announces Leadership Transition Marking Next Evolution of Growth

    Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director January 5, 2026 7:00 a.m. CET Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that Karen Massey, current Chief Operating Officer, will transition to Chief Executive Officer and Executive Director and Tim Van Hauwermeiren, current Chief Executive Officer, will transition to non-Executive Director and Chairman of the Board of Directors. Tim will succeed Peter Verhaeghe, w

    1/5/26 1:00:00 AM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director

    January 16, 2023 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday, February 27, 2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration f

    1/16/23 1:30:00 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    argenx Appoints Ana Cespedes to Board of Directors

    December 12, 2022 Amsterdam, the Netherlands – argenx SE ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that during the extraordinary general meeting of shareholders held today at 12:00pm CET, Ana Cespedes was appointed as non-executive director to its Board of Directors. Ana Cespedes brings robust experience across a broad range of critical areas for commercialization and access, as well as for organizational effectiveness. The voting result and all documents relating to the shareholders' meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings.

    12/12/22 4:01:00 PM ET
    $ARGX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care